Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, e-mail us.
Jan 14, 2015
BioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema
Jan 6, 2015
BioCryst to Present at J.P. Morgan Healthcare Conference
View all releases »
Rob Bennett, Vice President Investor Relations & Operations
For more information click here.
Questions about stock transfers and lost certificates should be directed to the transfer agent:
American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
1-800-937-5449 (toll free in US and Canada)
1-718-921-8200 (callers outside the US and Canada)